Compare ResMed Inc. (RMD) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs SPDR Kensho Final Frontiers ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while SPDR Kensho Final Frontiers ETF trades at $106.56. The key difference: ResMed Inc. pays a 1.19% dividend while SPDR Kensho Final Frontiers ETF pays none, and SPDR Kensho Final Frontiers ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | ROKT | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $283.28 | $136.68 |
52-Week Low | $182.82 | $71.62 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
